2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1604

Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE
Abstract Number: 1605

Lupus Low Disease Activity State Protects Against Most Subtypes of Organ Damage in SLE
Abstract Number: 1606

Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor
Abstract Number: 1607

Tumor-Related Autoantibodies and Cancers in SLE: A Case-Control Study from a Single Centre
Abstract Number: 1608

Entheseal Involvement in Systemic Lupus Erythematosus: An Ultrasound Study
Abstract Number: 1609

Telomere Length and Coronary Artery Atherosclerosis in Patients with Systemic Lupus Erythematosus
Abstract Number: 1610

The Impact of Alcohol Use on Cardiovascular Events and Overall Mortality in Women with Systemic Lupus Erythematosus
Abstract Number: 1611

Increased Body Mass Index May Not be a Risk Factor for the Development of Lupus Nephritis
Abstract Number: 1612

Primary Respiratory Disease in Patients with Systemic Lupus Erythematosus: Data from the Spanish Rheumatology Society Lupus Registry (RELESSER) Cohort
Abstract Number: 1613

Natural History of Disease Activity and Damage in Patients with Cutaneous Lupus Erythematosus on Standard of Care Treatments Using Longitudinal Registries from Two Academic Dermatology Centers
Abstract Number: 1614

“Do You Know What I Mean?” a Tool to Understand What Lupus Patients Comprehend
Abstract Number: 1615

Assessment of a Cognitive Impairment Measure in Systemic Lupus Erythematosus
Abstract Number: 1616

Early and Late Onset Biopsy Proven Lupus Nephritis without Other Associated Autoimmune Diseases: Severity and Long-Term Outcome
Abstract Number: 1617

Autoimmune Diseases in Patients with Cutaneous Lupus Erythematosus
Abstract Number: 1618

Risk Factors for Development of Early Infectious and Non-Infectious Complications in Systemic Lupus Erythematosus Patients Undergoing Major Surgery

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].